Philidor Calls Short-Sellers 'Discredited' And 'Patently False'; Citron's Andrew Left Responds

Valeant Pharmaceuticals Intl Inc VRX shares are relatively unchanged in Tuesday's after hours session following a press release from Philidor. The specialty pharma company said it's "deeply disappointed" its working relationship with Valeant has ended, adding that it's unfortunate "market forces, media misperceptions, and inflammatory, patently false reports by discredited short-sellers" were responsible.

Philidor added it will continue to work closely with regulators to address outstanding inquiries.

In an exclusive call with Benzinga, Citron Research's Andrew Left -- who said the stock is worth $50 and asked "could this be the Pharmaceutical Enron?" in late October -- responded.

According to Left, the statement's mention of short-sellers shows where the company's focus has been over the past couple weeks. In other words, Philidor is focusing on exterior factors and not its own business.

A Philidor spokesperson had no comment on the release, and said the company will not conduct any media interviews in the immediate future.